[Therapeutic use Hibiscus sabadariffa extract in the treatment of hypercholesterolemia. A randomized clinical trial]

Rev Med Inst Mex Seguro Soc. Sep-Oct 2011;49(5):469-80.
[Article in Spanish]

Abstract

Objective: to compare the effectiveness, safety and tolerability of Hibiscus sabadariffa extract (SHE) versus pravastatin in hypercholesterolemia.

Methods: double blind and controlled clinical trial. Men and women with hypercholesterolemia ≥ 220 mg/dL, and over 30 years without previous treatment were included.

Treatments: Experimental I, SHE standardized 10 mg of anthocyanins, control, 20 mg of pravastatin; Experimental II, extract of H. sabdariffa, standardized to 20 mg of anthocyanins for 12 weeks. SHE Data analysis with Anova and χ(2) tests were used.

Results: we included 104 patients, at baseline there were no significant differences in age, weight, BMI, total cholesterol, HDL, LDL, VLDL or triglycerides. At the end of the study, the experimental I group reduced triglycerides (p ≤0.0001), the control treatment reduced triglycerides, total cholesterol and its fractions (p = 0.02), and finally, the experimental treatment II reduced triglycerides (p = 0.0001). The three treatments showed high percentages (> 96) of safety and tolerability, without showing significant differences (p ≥ 0.57).

Conclusions: the treatments, with 10 and 20 mg of anthocyanins reduce triglycerides. The control treatment showed the greatest effect on lowering total cholesterol and fractions compared to experimental treatments.

Publication types

  • Comparative Study
  • English Abstract
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Anticholesteremic Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Hibiscus*
  • Humans
  • Hypercholesterolemia / drug therapy*
  • Male
  • Middle Aged
  • Phytotherapy*
  • Plant Extracts / therapeutic use*
  • Pravastatin / therapeutic use*

Substances

  • Anticholesteremic Agents
  • Plant Extracts
  • Pravastatin